Andrew Nicholson is head of diagnostic thoracic pathology at the Royal Brompton Hospital and Honorary Professor of Respiratory Pathology, National Heart and Lung Institute, Imperial College London.
Professor Andrew Nicholson trained at Oxford University and then St Bartholomew’s Hospital, London. He lectures regularly at international conferences, and has co-organised several international meetings.
He is a member of the International Association for the Study of Lung Cancer (IASLC) pathology panel, membership committee and staging committee. He is specialist advisor to the Royal College of Pathologists for lung cancer and a member of the Department of Health Advisory Group for lung cancer and mesothelioma. He is General Secretary for the British Division of the International Academy of Pathologists.
He has co-authored over 200 publications, predominantly on interstitial lung disease and cancer (lung and mesothelioma), being involved in several committees internationally producing guidelines for the management of idiopathic pulmonary fibrosis and lung cancer. He also wrote sections for the most recent WHO classification of lung tumours. He has co-authored Pathology of the Lung, 2nd Edition (3rd now in press), which won first prize in the basic and clinical sciences section of the BMA book awards in 2006, and is currently co-writing the Armed Forces Institute of Pathology fascicle on lung tumours.
et al., 2021, Large cell neuroendocrine lung carcinoma: consensus statement from The British Thoracic Oncology Group and the Association of Pulmonary Pathologists, British Journal of Cancer, ISSN:0007-0920
et al., 2021, Integrated genomics point to immune vulnerabilities in pleural mesothelioma, Scientific Reports, ISSN:2045-2322
Ravaglia C, Nicholson AG, 2021, Biopsy in interstitial lung disease: specific diagnosis and the identification of the progressive fibrotic phenotype, Current Opinion in Pulmonary Medicine, Vol:27, ISSN:1070-5287, Pages:355-362
et al., 2021, Chronic lung diseases are associated with gene expression programs favoring SARS-CoV-2 entry and severity, Nature Communications, Vol:12
et al., 2021, Y disruption, autosomal hypomethylation and poor male lung cancer survival, Scientific Reports, Vol:11, ISSN:2045-2322